Early Detection of Alzheimer's: Where Do We Go From Here?

Advances in Long Term Care Medicine

Inhoud geleverd door ReachMD. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door ReachMD of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

13+ y ago

MP3•Thuis aflevering

Gearchiveerde serie ("Inactieve feed" status)

When? This feed was archived on June 27, 2023 09:56 (10M ago). Last successful fetch was on August 01, 2022 15:09 (1+ y ago)

Why? Inactieve feed status. Onze servers konden geen geldige podcast feed ononderbroken ophalen.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Host: Eric Tangalos, MD
Guest: James E. Galvin, MD, MPH
Early detection of various conditions can help physicians better manage and treat their patients, and Alzheimer's is no exception. What early screening tests of cognitive impairment or dementia should be administered by primary care providers help detect when the disease process is beginning? Dr. James Galvin, professor in the departments of neurology and psychiatry at New York University Langone Medical Center in New York City, joins host Dr. Eric Tangalos to discuss the correlation between higher scores on cognitive impairment screening tests (such as the AD8 dementia screening test) and the presence of biomarkers for Alzheimer's. How effective is second stage confirmation of Alzheimer's with the use of biomarkers, and what role will biomarkers play in development of new therapies for this condition?

54 afleveringen

#Medicine #Science #Long Term Care #ReachMD #Health and Well-Being